|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Maris JM, Hogarty MD, Bagatell R and Cohn
SL: Neuroblastoma. Lancet. 369:2106–2120. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
DuBois SG, Kalika Y, Lukens JN, Brodeur
GM, Seeger RC, Atkinson JB, Haase GM, Black CT, Perez C, Shimada H,
et al: Metastatic sites in stage IV and IVS neuroblastoma correlate
with age, tumor biology, and survival. J Pediatr Hematol Oncol.
21:181–189. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cotterill SJ, Parker L, More L and Craft
AW: Neuroblastoma: Changing incidence and survival in young people
aged 0–24 years. A report from the North of England Young Persons'
Malignant Disease Registry. Med Pediatr Oncol. 36:231–234. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cohn SL, Pearson AD, London WB, Monclair
T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, et
al: ; INRG Task Force: The International Neuroblastoma Risk Group
(INRG) classification system: An INRG Task Force report. J Clin
Oncol. 27:289–297. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang XH, Tang F, Shin J and Cunningham JM:
A c-Myc-regulated stem cell-like signature in high-risk
neuroblastoma: A systematic discovery (Target neuroblastoma
ESC-like signature). Sci Rep. 7:412017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
DeNardo BD, Holloway MP, Ji Q, Nguyen KT,
Cheng Y, Valentine MB, Salomon A and Altura RA: Quantitative
phosphoproteomic analysis identifies activation of the RET and
IGF-1R/IR signaling pathways in neuroblastoma. PLoS One.
8:e825132013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Martinez MA, Ubeda A, Cid MA and Trillo
MA: The proliferative response of NB69 human neuroblastoma cells to
a 50 Hz magnetic field is mediated by ERK1/2 signaling. Cell
Physiol Biochem. 29:675–686. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vieira GC, Chockalingam S, Melegh Z,
Greenhough A, Malik S, Szemes M, Park JH, Kaidi A, Zhou L,
Catchpoole D, et al: LGR5 regulates pro-survival MEK/ERK and
proliferative Wnt/β-catenin signalling in neuroblastoma.
Oncotarget. 6:40053–40067. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vujic I, Posch C, Sanlorenzo M, Yen AJ,
Tsumura A, Kwong A, Feichtenschlager V, Lai K, Arneson DV,
Rappersberger K, et al: Mutant NRASQ61 shares signaling
similarities across various cancer types-potential implications for
future therapies. Oncotarget. 5:7936–7944. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pugh TJ, Morozova O, Attiyeh EF,
Asgharzadeh S, Wei JS, Auclair D, Carter SL, Cibulskis K, Hanna M,
Kiezun A, et al: The genetic landscape of high-risk neuroblastoma.
Nat Genet. 45:279–284. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Eleveld TF, Oldridge DA, Bernard V, Koster
J, Colmet Daage L, Diskin SJ, Schild L, Bentahar NB, Bellini A,
Chicard M, et al: Relapsed neuroblastomas show frequent RAS-MAPK
pathway mutations. Nat Genet. 47:864–871. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schramm A, Köster J, Assenov Y, Althoff K,
Peifer M, Mahlow E, Odersky A, Beisser D, Ernst C, Henssen AG, et
al: Mutational dynamics between primary and relapse neuroblastomas.
Nat Genet. 47:872–877. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Roberts PJ and Der CJ: Targeting the
Raf-MEK-ERK mitogen-activated protein kinase cascade for the
treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Montagut C and Settleman J: Targeting the
RAF-MEK-ERK pathway in cancer therapy. Cancer Lett. 283:125–134.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yu Z, Ye S, Hu G, Lv M, Tu Z, Zhou K and
Li Q: The RAF-MEK-ERK pathway: Targeting ERK to overcome obstacles
to effective cancer therapy. Future Med Chem. 7:269–289. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang L, Wang J, Wu Y, Wu J, Pang S, Pan R
and Wen T: A novel function of dcf1 during the differentiation of
neural stem cells in vitro. Cell Mol Neurobiol. 28:887–894. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li X, Feng R, Huang C, Wang H, Wang J,
Zhang Z, Yan H and Wen T: MicroRNA-351 regulates TMEM 59 (DCF1)
expression and mediates neural stem cell morphogenesis. RNA Biol.
9:292–301. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xie Y, Li Q, Yang Q, Yang M, Zhang Z, Zhu
L, Yan H, Feng R, Zhang S, Huang C, et al: Overexpression of DCF1
inhibits glioma through destruction of mitochondria and activation
of apoptosis pathway. Sci Rep. 4:37022014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu Q, Feng R, Chen Y, Luo G, Yan H, Chen
L, Lin R, Ding Y and Wen T: Dcf1 triggers dendritic spine formation
and facilitates memory acquisition. Mol Neurobiol. 55:763–775.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu Q, Chen Y, Li Q, Wu L and Wen T: Dcf1
regulates neuropeptide expression and maintains energy balance.
Neurosci Lett. 650:1–7. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xie Y, Li Q, Yang Q, Yang M, Zhang Z, Zhu
L, Yan H, Feng R, Zhang S, Huang C, et al: Overexpression of DCF1
inhibits glioma through destruction of mitochondria and activation
of apoptosis pathway. Sci Rep. 4:pp. 37022014, https://doi.org/10.1038/srep03702
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim MS, Yu JM, Kim HJ, Kim HB, Kim ST,
Jang SK, Choi YW, Lee DI and Joo SS: Ginsenoside Re and Rd enhance
the expression of cholinergic markers and neuronal differentiation
in Neuro-2a cells. Biol Pharm Bull. 37:826–833. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Weibel S, Hofmann E, Basse-Luesebrink TC,
Donat U, Seubert C, Adelfinger M, Gnamlin P, Kober C, Frentzen A,
Gentschev I, et al: Treatment of malignant effusion by oncolytic
virotherapy in an experimental subcutaneous xenograft model of lung
cancer. J Transl Med. 11:1062013.https://doi.org/10.1186/1479-5876-11-106
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pagano M, Pepperkok R, Verde F, Ansorge W
and Draetta G: Cyclin A is required at two points in the human cell
cycle. EMBO J. 11:961–971. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chipuk JE, Fisher JC, Dillon CP, Kriwacki
RW, Kuwana T and Green DR: Mechanism of apoptosis induction by
inhibition of the anti-apoptotic BCL-2 proteins. Proc Natl Acad Sci
USA. 105:20327–20332. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ambrosini G, Adida C and Altieri DC: A
novel anti-apoptosis gene, survivin, expressed in cancer and
lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC,
Hwang JI, Chung CW, Jung YK and Oh BH: An anti-apoptotic protein
human survivin is a direct inhibitor of caspase-3 and-7.
Biochemistry. 40:1117–1123. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lavoie JN, L'Allemain G, Brunet A, Müller
R and Pouysségur J: Cyclin D1 expression is regulated positively by
the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol
Chem. 271:20608–20616. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Caunt CJ, Sale MJ, Smith PD and Cook SJ:
ME K1 and MEK2 inhibitors and cancer therapy: The long and winding
road. Nat Rev Cancer. 15:577–592. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu Y, Zhang X, Yang B, Zhuang H, Guo H,
Wei W, Li Y, Chen R, Li Y and Zhang N: Demethylation-induced
overexpression of Shc3 drives c-Raf-independent activation of
MEK/ERK in HCC. Cancer Res. 78:2219–2232. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yang C, Zheng W and Du W: CXCR3A
contributes to the invasion and metastasis of gastric cancer cells.
Oncol Rep. 36:1686–1692. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hou H, Ge C, Sun H, Li H, Li J and Tian H:
Tunicamycin inhibits cell proliferation and migration in
hepatocellular carcinoma through suppression of CD44s and the
ERK1/2 pathway. Cancer Sci. 109:1088–1100. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhao H, Liu B and Li J: LIM and SH3
protein 1 knockdown suppresses proliferation and metastasis of
colorectal carcinoma cells via inhibition of the mitogen-activated
protein kinase signaling pathway. Oncol Lett. 15:6839–6844.
2018.PubMed/NCBI
|
|
36
|
Ferreira-Silva GA, Lages CC, Sartorelli P,
Hasegawa FR, Soares MG and Ionta M: Casearin D inhibits ERK
phosphorylation and induces downregulation of cyclin D1 in HepG2
cells. Toxicol In Vitro. 38:27–32. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xu X, Wang Q, He Y, Ding L, Zhong F, Ou Y,
Shen Y, Liu H and He S: ADP-ribosylation factor 1 (ARF1) takes part
in cell proliferation and cell adhesion-mediated drug resistance
(CAM-DR). Ann Hematol. 96:847–858. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yan Y, Wang L, He J, Liu P, Lv X and Zhang
Y, Xu X, Zhang L and Zhang Y: Synergy with interferon-lambda 3 and
sorafenib suppresses hepatocellular carcinoma proliferation. Biomed
Pharmacother. 88:395–402. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Uehling DE and Harris PA: Recent progress
on MAP kinase pathway inhibitors. Bioorg Med Chem Lett.
25:4047–4056. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wu PK and Park JI: MEK1/2 Inhibitors:
Molecular activity and resistance mechanisms. Semin Oncol.
42:849–862. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Serini S and Calviello G: Modulation of
Ras/ERK and phosphoinositide signaling by long-chain n-3 PUFA in
breast cancer and their potential complementary role in combination
with targeted drugs. Nutrients. 9:1852017.doi:10.3390/nu9030185.
View Article : Google Scholar :
|
